Fed. Circ. Fines Sun, Caraco Attys In Eloxatin IP Case

Law360, New York (March 29, 2011, 5:20 PM EDT) -- The Federal Circuit sanctioned attorneys for Sun Pharmaceutical Industries Ltd. and Caraco Pharmaceutical Laboratories Ltd. Tuesday for the extensive use of improper confidentiality markings in Sanofi-Aventis U.S. LLC's patent suit over a generic version of colon cancer drug Eloxatin, fining them $1,000.

A three-judge panel of the U.S. Court of Appeals for the Federal Circuit said Sun and Caraco's counsel Katten Muchin Rosenman LLP deserved the sanctions.

“At oral argument we did not suggest that marking the license and settlement agreements as confidential was itself sanctionable,”...
To view the full article, register now.